Metsera (NASDAQ:MTSR – Get Free Report) issued its earnings results on Wednesday. The company reported ($3.52) EPS for the quarter, Zacks reports.
Metsera Price Performance
MTSR opened at $29.16 on Wednesday. Metsera has a fifty-two week low of $23.08 and a fifty-two week high of $32.81.
Analysts Set New Price Targets
Several analysts have recently commented on MTSR shares. Guggenheim started coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective on the stock. Evercore ISI assumed coverage on Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating on the stock. Cantor Fitzgerald started coverage on Metsera in a research note on Tuesday, February 25th. They set an “overweight” rating for the company. Finally, Bank of America assumed coverage on Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $38.00 target price on the stock.
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
- Five stocks we like better than Metsera
- Insider Buying Explained: What Investors Need to Know
- Palantir Setting Up to Be a Big Winner With New Defense Spending
- How to Effectively Use the MarketBeat Ratings Screener
- Advanced Micro Devices Can Double in Price: Here’s Why
- How to Use High Beta Stocks to Maximize Your Investing Profits
- How Disney’s Experiences Segment Can Restore the House of Mouse
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
